On Friday, Health care stocks were descended lately accompanied by the NYSE Health Care Sector Index declining 1.6% and shares of health care companies in the S&P 500 plummeting 1.4% as a group.
Headline From Biotech Sector:
Ignyta, Inc. (Nasdaq:RXDX), a precision oncology biotechnology company, declared today that Pratik S. Multani, M.D., M.S., has been designated as Chief Medical Officer, assuming liability for the role from Adrian Senderowicz, M.D., who has been designated to the newly-created role of Clinical and Regulatory Strategy Officer. Dr. Multani received a B.S. degree in chemistry and biology from Yale University and an M.D. from Harvard Medical School, followed by an M.S. degree in epidemiology at the Harvard School of Public Health.
Comprehensive data (along with news and profiles), for Friday’s Champions in U.S Stocks, among biotech sector, is demonstrated underneath:
ImmunoGen, (NASDAQ:IMGN), skyrocketed 23.06% to settle at $7.63, during its last trading session, soon after a biotechnology company, stated financial results for the three-month period ended December 31, 2014 – the second quarter of the Company’s 2015 fiscal year (2QFY2015). ImmunoGen also provided an update on product programs and reiterated its financial guidance.
ImmunoGen, Inc. (IMGN), is a biotechnology company. The Company develops targeted anticancer therapeutics. The Company has three wholly-owned product candidates in clinical testing, with seven additional compounds in the clinic through its partnerships with Amgen, Bayer HealthCare, Biotest and Sanofi.
Spark Therapeutics, (NASDAQ:ONCE), went higher breaking all the records to 117.39% and settled at $50.00, during its last trading session, as gene therapy products developer, declared the pricing of its initial public offering of 7,000,000 shares of ordinary stock at a public offering price of $23.00 per share, before underwriting discounts. All of the shares in the offering are being sold by Spark. In addition, Spark has granted the underwriters an option to purchase up to 1,050,000 additional shares of ordinary stock at the public offering price, less the underwriting discount.
Spark Therapeutics (ONCE), focuses on the development of gene therapy products for patients suffering from debilitating genetic diseases. The organization is developing SPK-RPE65, which is in Phase III clinical trial for the treatment of inherited retinal dystrophies, a group of rare blinding conditions caused by non-sex linked, or autosomal recessive, mutations in the RPE65 gene.
MannKind Corporation (NASDAQ:MNKD), inclined 1.11% to close at $6.35, during its last trading session, after a biopharmaceutical company, confirmed that Alfred Mann, the company’s founder, stepped down from his role as Chief Executive Officer effective January 9, 2015 and will transition to Executive Chairman. Mr. Mann proposes to remain engaged with the company in business matters, counting those regarding development and financing of MannKind’s future therapies. On January 9, 2015, MannKind’s Board of Directors designated Hakan Edstrom, current President of MannKind, as the new Chief Executive Officer of the company. Mr. Edstrom will retain his title as President.
MannKind Corporation (MNKD), a biopharmaceutical company focuses on the discovery, development, and commercialization of therapeutic products for diabetes and cancer in the United States.
Intercept Pharmaceuticals Inc (NASDAQ:ICPT), rose 17.77%, following the news that its investigational product obeticholic acid (OCA) has received “breakthrough therapy designation” from the U.S. Food and Drug Administration (FDA) for the treatment of patients with nonalcoholic steatohepatitis (NASH) with liver fibrosis. This indication constitutes a population of patients with a serious and life-threatening condition reflected by a higher risk of progression to cirrhosis and liver failure. OCA is presently being developed for the treatment of several chronic liver diseases, counting primary biliary cirrhosis (PBC), NASH and primary sclerosing cholangitis (PSC).
Intercept Pharmaceuticals, (ICPT), a development stage biopharmaceutical company, focuses on the development and commercialization of novel therapeutics to treat chronic liver and intestinal diseases utilizing its proprietary bile acid chemistry.
